tiprankstipranks
Trending News
More News >
Caplin Point Laboratories Limited (IN:CAPLIPOINT)
:CAPLIPOINT
India Market
Advertisement

Caplin Point Laboratories Limited (CAPLIPOINT) Price & Analysis

Compare
2 Followers

CAPLIPOINT Stock Chart & Stats


CAPLIPOINT FAQ

What was Caplin Point Laboratories Limited’s price range in the past 12 months?
Caplin Point Laboratories Limited lowest stock price was ₹1551.05 and its highest was ₹2636.00 in the past 12 months.
    What is Caplin Point Laboratories Limited’s market cap?
    Caplin Point Laboratories Limited’s market cap is ₹158.53B.
      When is Caplin Point Laboratories Limited’s upcoming earnings report date?
      Caplin Point Laboratories Limited’s upcoming earnings report date is Nov 06, 2025 which is in 69 days.
        How were Caplin Point Laboratories Limited’s earnings last quarter?
        Caplin Point Laboratories Limited released its earnings results on Aug 07, 2025. The company reported ₹20.1 earnings per share for the quarter, beating the consensus estimate of N/A by ₹20.1.
          Is Caplin Point Laboratories Limited overvalued?
          According to Wall Street analysts Caplin Point Laboratories Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Caplin Point Laboratories Limited pay dividends?
            Caplin Point Laboratories Limited pays a Quarterly dividend of ₹3 which represents an annual dividend yield of 0.25%. See more information on Caplin Point Laboratories Limited dividends here
              What is Caplin Point Laboratories Limited’s EPS estimate?
              Caplin Point Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Caplin Point Laboratories Limited have?
              Caplin Point Laboratories Limited has 76,011,696 shares outstanding.
                What happened to Caplin Point Laboratories Limited’s price movement after its last earnings report?
                Caplin Point Laboratories Limited reported an EPS of ₹20.1 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 6.714%.
                  Which hedge fund is a major shareholder of Caplin Point Laboratories Limited?
                  Currently, no hedge funds are holding shares in IN:CAPLIPOINT

                  Company Description

                  Caplin Point Laboratories Limited

                  Caplin Point Laboratories Limited is a pharmaceutical company based in India that specializes in the development, manufacturing, and distribution of a wide range of pharmaceutical products. The company operates in the sectors of generic pharmaceuticals and over-the-counter (OTC) medications. Its core products include formulations in various dosage forms such as tablets, capsules, ointments, and injectables, catering primarily to emerging markets.

                  Caplin Point Laboratories Limited (CAPLIPOINT) Earnings & Revenues

                  CAPLIPOINT Stock 12 Month Forecast

                  Average Price Target

                  ₹2,315.00
                  ▲(7.29% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1819":"₹1,819","2506":"₹2,506","1990.75":"₹1,990.8","2162.5":"₹2,162.5","2334.25":"₹2,334.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2315,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹2.31K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2315,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹2.31K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2315,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹2.31K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1819,1990.75,2162.5,2334.25,2506],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1987.5,2012.6923076923076,2037.8846153846155,2063.076923076923,2088.269230769231,2113.4615384615386,2138.653846153846,2163.846153846154,2189.0384615384614,2214.230769230769,2239.423076923077,2264.6153846153848,2289.8076923076924,{"y":2315,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1987.5,2012.6923076923076,2037.8846153846155,2063.076923076923,2088.269230769231,2113.4615384615386,2138.653846153846,2163.846153846154,2189.0384615384614,2214.230769230769,2239.423076923077,2264.6153846153848,2289.8076923076924,{"y":2315,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1987.5,2012.6923076923076,2037.8846153846155,2063.076923076923,2088.269230769231,2113.4615384615386,2138.653846153846,2163.846153846154,2189.0384615384614,2214.230769230769,2239.423076923077,2264.6153846153848,2289.8076923076924,{"y":2315,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1878.11,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2077.41,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2032.82,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2231.35,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2505.07,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2076.36,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1820.22,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1976.2,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1882.43,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2158.5,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1998.9,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1998.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1987.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Alembic Pharmaceuticals Limited
                  Glenmark Life Sciences Limited
                  Granules India Limited
                  NATCO Pharma Limited
                  Neuland Laboratories Ltd.
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis